25,516 Shares in Novo Nordisk A/S $NVO Bought by SageView Advisory Group LLC

SageView Advisory Group LLC purchased a new stake in shares of Novo Nordisk A/S (NYSE:NVO) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 25,516 shares of the company’s stock, valued at approximately $1,416,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Beacon Financial Group boosted its stake in Novo Nordisk A/S by 4.3% in the 3rd quarter. Beacon Financial Group now owns 4,307 shares of the company’s stock worth $239,000 after purchasing an additional 178 shares during the period. Kavar Capital Partners Group LLC grew its position in shares of Novo Nordisk A/S by 0.6% in the 3rd quarter. Kavar Capital Partners Group LLC now owns 32,631 shares of the company’s stock worth $1,811,000 after buying an additional 200 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its stake in Novo Nordisk A/S by 5.7% in the 3rd quarter. SeaBridge Investment Advisors LLC now owns 3,735 shares of the company’s stock worth $207,000 after purchasing an additional 200 shares in the last quarter. Joel Isaacson & Co. LLC boosted its position in Novo Nordisk A/S by 1.0% in the third quarter. Joel Isaacson & Co. LLC now owns 21,084 shares of the company’s stock valued at $1,170,000 after buying an additional 200 shares during the last quarter. Finally, Revolve Wealth Partners LLC increased its holdings in shares of Novo Nordisk A/S by 8.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after purchasing an additional 200 shares in the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.2%

Novo Nordisk A/S stock opened at $38.82 on Thursday. The firm has a market capitalization of $173.31 billion, a P/E ratio of 11.19 and a beta of 0.73. The stock’s fifty day simple moving average is $50.69 and its 200-day simple moving average is $52.02. Novo Nordisk A/S has a twelve month low of $35.85 and a twelve month high of $82.57. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share for the quarter, beating the consensus estimate of $0.90 by $0.11. The business had revenue of $12.43 billion during the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Novo Nordisk A/S Dividend Announcement

The company also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be issued a $1.2751 dividend. The ex-dividend date of this dividend is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio is 52.74%.

Wall Street Analysts Forecast Growth

NVO has been the topic of a number of recent research reports. BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Thursday, February 5th. CICC Research began coverage on Novo Nordisk A/S in a research report on Friday, January 9th. They issued an “outperform” rating and a $73.50 price target for the company. Jefferies Financial Group raised Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a research note on Thursday, February 12th. Kepler Capital Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Finally, Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price on the stock in a research note on Tuesday, March 3rd. Four research analysts have rated the stock with a Buy rating and nineteen have assigned a Hold rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S currently has an average rating of “Hold” and a consensus target price of $49.93.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Deal with Hims & Hers resolves a legal feud and opens the telehealth channel to sell FDA‑approved Ozempic and Wegovy, which could shift patients away from compounded alternatives and support volume recovery. Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
• Neutral Sentiment: India’s regulator warned against direct or surrogate advertising for weight‑loss drugs, which could constrain marketing strategies in a fast‑growing market but is not an immediate sales sanction. India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
• Negative Sentiment: FDA issued a warning letter over failures in post‑marketing adverse event reporting tied to semaglutide (Ozempic/Wegovy), citing potential unreported serious events including deaths and a suicide — this raises regulatory risk and a near‑term compliance/oversight overhang. FDA issues warning to Novo Nordisk on unreported semaglutide safety events
• Negative Sentiment: Sell‑side and street pressure: TD Cowen downgraded NVO and other analysts flag that the pipeline may not blunt semaglutide loss‑of‑exclusivity (LOE) headwinds — reinforcing negative sentiment after guidance cuts. Novo Nordisk downgraded as pipeline ‘not poised to blunt semaglutide LOE’
• Negative Sentiment: Investor legal pressure: law firm Pomerantz announced an investigation into Novo Nordisk investors, signaling possible litigation risk and additional headline volatility. Pomerantz law firm investigates claims on behalf of investors of Novo Nordisk
• Negative Sentiment: Competitive pressure: Eli Lilly’s aggressive investments and programs (including China expansion and employer/coverage initiatives) keep the GLP‑1 market intensely competitive, which could pressure Novo’s pricing and market share over time. The Real Reason Eli Lilly Is Pouring $3 Billion Into China

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.